Truist raised the firm’s price target on Corcept Therapeutics to $65 from $44 and keeps a Buy rating on the shares. The company’s Phase 3 GRACE data was well-received, while its key opinion leader panel discussing management of hyperglycemia secondary to hypercortisolism resonated well with endocrinologists, the analyst tells investors in a research note. The firm adds that it is introducing a diabetes model with “highly conservative” assumptions in raising its price target on Corcept and will look ahead to additional data this Friday at Heart in Diabetes Conference in Philadelphia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target raised to $70.50 from $61 at Ladenburg
- Corcept Therapeutics announces Phase 3 GRACE trial meets primary endpoint
- Corcept Therapeutics price target raised to $40 from $38 at H.C. Wainwright